Xilio Therapeutics, Inc. cash flow to debt ratio of -71.79% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Xilio Therapeutics, Inc.'s free cash flow has increased -70.08% from $-18.41M last year to $-5.51M, signaling increasing performance

Xilio Therapeutics, Inc.'s debt to equity ratio is 0.09, which means that the company's assets are healthy financed, signaling financial stability. READ MORE: A ratio under 0.60 means the company finances its assets with own equity, signaling financial stability and good management.

Xilio Therapeutics, Inc.'s debt has decreased relative to shareholder equity from 0.46 last year to 0.09 today, signaling strengthened financials

Xilio Therapeutics, Inc. has negative EBITDA, making leverage ratio unreliable

Xilio Therapeutics, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Xilio Therapeutics, Inc.'s profit margin has increased (-93.63%) in the last year from -918.05% to -58.52%, signaling increasing performance

Xilio Therapeutics, Inc.'s short-term assets of $145.03M exceed its short-term liabilities of $56.27M

Xilio Therapeutics, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Xilio Therapeutics, Inc.'s return on equity of -117.24%, is lower than 15.00%, indicating bad performance

Xilio Therapeutics, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Xilio Therapeutics, Inc. had positive net income in only 0.00 out of 5 years, indicating unstable earnings

Xilio Therapeutics, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Xilio Therapeutics, Inc. has negative free cash flow, indicating cash burn

Xilio Therapeutics, Inc.'s yearly earnings has increased -39.84% since last year from $-58.24M to $-35.04M, signaling increasing performance

Xilio Therapeutics, Inc.'s yearly revenue has increased 589.88% since last year from $6.34M to $43.77M, signaling increasing performance

ROIC -34.65% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Xilio Therapeutics, Inc. has insufficient revenue history to calculate 3-year revenue CAGR.

Xilio Therapeutics, Inc. had revenue growth in 5.00 out of 5 years, indicating consistent revenue performance

Xilio Therapeutics, Inc. had positive ROE in only 0.00 out of 5 years, indicating inconsistent returns on equity

Xilio Therapeutics, Inc. is overvalued relative to its fair value price of 5.67 based on Discounted Cash Flow model

Xilio Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Xilio Therapeutics, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Xilio Therapeutics, Inc. has an EV/EBITDA ratio of 2.81x, which is below the 20.00x threshold, indicating reasonable valuation relative to its operating earnings

Xilio Therapeutics, Inc. has insufficient data to evaluate this check.

Xilio Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Xilio Therapeutics, Inc. has a price-to-book ratio of 20.39x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value

Xilio Therapeutics, Inc. has a price-to-sales ratio of 1.11x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue